Floatz logo

Trametinib

Astrocytic Tumor

Novartis PharmaceuticalsSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Astrocytic Tumor cohort.

Asset / SponsorPhaseRating
Carboplatin
Oliver Jonas
Phase 2BB
Irinotecan
Julie Krystal
Phase 2BB
(+)-Vincristine
Novartis Pharmaceuticals
Phase 2BB
Dabrafenib
Novartis Pharmaceuticals
Phase 4BB
Camustine
Radiation Therapy Oncology Group
Phase 3B

View all 39 →

Same molecule, other indications

Trametinib is also rated in:

melanomaActive
BB
Indicative · Phase 4
69 / 100
View asset →
anaplastic pleomorphic xanthoastrocytomaActive
BB
Indicative · Phase 4
69 / 100
View asset →
anaplastic oligodendrogliomaActive
BB
Indicative · Phase 4
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →